Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2020 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
May 26, 2020 16:01 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
May 15, 2020 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
May 12, 2020 06:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
May 11, 2020 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP...
May 07, 2020 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
May 04, 2020 16:01 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Announce First Quarter 2020 Financial Results

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
April 29, 2020 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
March 12, 2020 07:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity

RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA Internal cGMP Manufacturing Ready to Support Upcoming Oncology Clinical Trials Cash Runway Extended into 2022 ...
March 03, 2020 16:01 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast

CAMBRIDGE, Mass., March 03, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right